The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the Pharmaceuticals, Biotechnology and Generics sectors of the overall health care industry, backed by a team of respected writers with many years of experience in the field.
Article Item
Published: 24/11/2009
The world’s largest drugmaker, USA-based Pfizer, is eyeing the Japanese generics market and, in an investment review of the company, Goldman Sachs said sales in emerging growth markets would become a significant factor in the company's revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer.
654 suspected adverse reactions to Panvax reported to Australia’s TGA in one month
The Australian national immunization program with the H1N1 2009 influenza vaccine Panvax, made by Fre ...
UK government settles out of court with DDSA Pharma
In a joint statement, the UK Department of Health and London-based DDSA Pharmaceuticals said they had ...
Spanish pharmaceutical market evolution
Data from the Spanish Ministry of Health and Consumer Affairs pertaining to the month of August of 20 ...
AMA praised for urging USA to facilitate clinical R&D of cannabinoid-based medicines
Cannabis Science, an emerging US pharmaceutical cannabis company, is hailing the call by the American ...
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff,’ Big Pharma is busy imp ...
Over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug ma ...
Narrow vote sees US Senate approve motion to debate Reid health reform bill
In a narrow vote, US Senate Democrats voted on Saturday night (November 21) to begin the official deb ...
Merck KGaA to boost R&D presence in China with $223 million investment
German drug major Merck KGaA is the latest in a string of multinationals to view China as a good base ...
EMEA starts sibutramine review, as FDA investigates Meridia
The European Medicines Agency (EMEA) says it has started a review of sibutramine-containing anti-obes ...
Meeting highlights from Europe’s CHMP November 16-19, 2009
Following its November 16-19 meetings, the European Medicines Agency (EMEA) says it has reviewed furt ...
